1. Comparative in vitro activity of garenoxacin against Chlamydia spp.
- Author
-
Donati M, Pollini GM, Sparacino M, Fortugno MT, Laghi E, and Cevenini R
- Subjects
- Animals, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Chlamydia Infections drug therapy, Chlamydia Infections microbiology, Chlamydia trachomatis growth & development, Chlamydia trachomatis isolation & purification, Chlamydophila pneumoniae growth & development, Chlamydophila pneumoniae isolation & purification, Chlamydophila psittaci growth & development, Chlamydophila psittaci isolation & purification, Humans, Indoles therapeutic use, Macrolides, Microbial Sensitivity Tests, Quinolones therapeutic use, Tetracyclines, Chlamydia trachomatis drug effects, Chlamydophila pneumoniae drug effects, Chlamydophila psittaci drug effects, Fluoroquinolones, Indoles pharmacology, Quinolones pharmacology
- Abstract
The in vitro susceptibilities of 33 isolates of Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci to a new quinolone drug, garenoxacin (BMS-284756), in comparison with levofloxacin, ciprofloxacin, doxycycline, erythromycin and roxithromycin, were determined. Garenoxacin was the most active of the quinolone drugs tested, with identical MIC and MBC, which ranged from 0.007 to 0.03 mg/L. The MIC and MBC of the other two quinolones tested, levofloxacin and ciprofloxacin, were also identical, ranging from 0.25 to 2 mg/L. The MICs and MBCs of doxycycline, erythromycin and roxithromycin were also determined.
- Published
- 2002
- Full Text
- View/download PDF